Stock Ratings / Health Care / EXOZ / options

ELUT (31) INMB (31) IMA (19) ESLA (39) ⌘ Pro Terminal →

eXoZymes Inc. (EXOZ) Options Positioning, Max Pain & Unusual Sweeps

$4.13 +0.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.13

eXoZymes Inc. (EXOZ) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $38.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EXOZ Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EXOZ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, eXoZymes Inc. (NASDAQ: EXOZ) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $4.13 (+0.49% 1D, market cap $38.2M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EXOZ ranks #782 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EXOZ compare to ELUT and INMB in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EXOZ carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ELUT (Elutia Inc. (Class A)) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $36.0M) and INMB (INmune Bio Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $44.4M). Among the 5-stock peer group, EXOZ leads on earnings multiple (N/A) while EXOZ leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EXOZ?

▼

Per EXOZ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002010788), eXoZymes Inc. generated $0 in revenue, -$9.2M in net income, and -$6.7M in free cash flow against $6.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.13 (-0.10%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EXOZ)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY EXOZ SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$5.05-20.8% Next Q

Q2 (-2Q)

Grade E$4.00-6.3% Next Q

Q3 (-1Q)

Grade E$3.75+10.1% Next Q

Current

Grade E$4.13-9.2% Hist 90D α

Trajectory: D (40) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EXOZ Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EXOZ currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.62) and Max Pain ($4.34) forces dealer call-delta covering toward $19.32.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EXOZ• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EXOZ Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (EXOZ)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for EXOZ.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EXOZ)

✓Walkthrough of EXOZ's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EXOZ // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -58.37%▼ DESCENDING CHANNEL

2026-11-02O $4.22H $4.22L $4.11C $4.13VOL 9.2K

RES: $5.48SUP: $3.17SMA50: $5.62SMA200: $7.73

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EXOZ Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EXOZ Butterfly Map → + Track EXOZ →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EXOZ today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EXOZ. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EXOZ today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EXOZ)

Health Care Rank #782 of 1016 ⚔️ ELUT vs EXOZ Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EXOZ vs. ELUT, INMB, IMA, ESLA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, eXoZymes Inc. (EXOZ) ranks #782 by composite RQD confidence (32/100, grade E) and #780 by equity capitalization ($38.2M). Within this direct 5-issuer industry benchmark cohort, EXOZ leads on earnings valuation at N/A trailing P/E, while EXOZ leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ESLA currently holds the highest overall quantitative score in the immediate peer group at 39/100 (D-) compared with EXOZ at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EXOZ ACTIVE eXoZymes Inc.	E	32/100	—	—	-35.0%	+0.49%	$38.2M	Benchmark Subject
ELUT Elutia Inc. (Class A)	E	31/100	—	53.7%	-35.0%	+2.89%	$36.0M	/elut-vs-exoz →
INMB INmune Bio Inc.	E	31/100	—	—	-35.0%	-9.37%	$44.4M	/inmb-vs-exoz →
IMA ImageneBio Inc.	E	19/100	—	—	-35.0%	+1.24%	$46.0M	/ima-vs-exoz →
ESLA Estrella Immunopharma Inc.	D-	39/100	—	—	-35.0%	-12.27%	$31.7M	/esla-vs-exoz →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002010788

In its most recent audited fiscal period (FY2025, filed 2025-12-31), eXoZymes Inc. (EXOZ) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$9.2M, operating cash flow of -$6.5M, and free cash flow of -$6.7M (+25.1% YoY). On the balance sheet, EXOZ closed FY2025 with $6.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$9.2M	-$6.5M	-$6.7M	$6.0M	—
FY2024 (FY)	2024-12-31	$0	-$5.9M	-$8.5M	-$8.9M	$13.0M	—
FY2023 (FY)	2023-12-31	$70.1K	-$2.0M	-$1.2M	-$1.2M	—	—

3. EXOZ Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EXOZ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does EXOZ compare to ELUT and INMB in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for EXOZ?

Where is EXOZ trading relative to its 50-day, 200-day, and 52-week technical levels?

EXOZ last traded at $4.13 (+0.49% on volume of 6,115 shares), positioning the stock -26.51% below its 50-day simple moving average ($5.62) and -46.57% below its 200-day simple moving average ($7.73). Across its 52-week range of $3.24 to $18.40, EXOZ sits at the 5.9% percentile with a 14-day RSI of 35.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.61 to $4.65).

EXOZ Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is EXOZ's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for EXOZ.

Direct Sub-Reports: EXOZ RQD Cockpit EXOZ 12M Forecast EXOZ Earnings & Move EXOZ Dividends & DRIP EXOZ Insiders & 13F EXOZ Whale Options EXOZ Profit Sankey EXOZ News & Why

Sector Peer Dials

Compare →

ELUT E

Elutia Inc. (Class A)

Estrella Immunopharma Inc.

EXOZ Core Snapshot

Market Cap $38.2M

Trailing / Fwd P/E — / —

Gross Profit Margin —

Return on Capital (ROIC) -35.0%

Free Cash Flow Yield -17.45%

12M Base Price Target $3.65

FREE TRADER TOOLS

Own EXOZ Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With EXOZ → 🏆 Trade EXOZ in $100K Prop Arena →

EXOZ Wire

Why It Moved →

Direct Company Event TradingView • 12h ago

eXoZymes Inc. Estimates – NASDAQ:EXOZ

Direct Company Event Stock Titan • 15h ago

A rare natural molecule is central to eXoZymes' plans for supplements

Direct Company Event Investing.com Nigeria • 18h ago

Exozymes CCO Damien Perriman sells $19,426 in stock By Investing.com

Direct Company Event https://www.siam.in/ • 21h ago

eXoZymes (EXOZ) Slips 1.50% to $5.25 as Shares Hold Above $5.00 Support - Butterfly Setup

Direct Company Event Stock Titan • 1d ago

Options for 10,000 shares at $6.28 go to Exozymes (EXOZ) director Marlett.

ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

EXOZ — eXoZymes Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:47:56Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating assigns a score of 32 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid" (per the Roarable RQD rating). Across its five pillars:

Fundamental Cash Engine: 9 / 20. Return on invested capital is -35% and FCF yield is -17.45% (per the Roarable RQD rating and market data). For a prospective investor, this means the business is currently consuming capital rather than generating it, so any valuation rests on future cash generation that the reported history does not yet show.
Whale 13F Flow: 3 / 20. The rating reflects institutional accumulation and options positioning as weak (per the Roarable RQD rating). The holders section contains no institutional data, so the specifics behind this score cannot be verified from the source data.
Insider Conviction: 3 / 20. The rating reflects SEC Form 4 and Congressional PTR flow as weak (per the Roarable RQD rating). The news wire does reference executive and director stock sales and option grants, which the investor should weigh against this score (per recent news and catalysts).
Macro Regime Fit: 7 / 20. Beta is 1.0 (per market data), indicating market-level sensitivity, and the rating notes sector sensitivity (per the Roarable RQD rating). Sector-level detail is not available in source data.
Forensic Balance Sheet: 10 / 20. The rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and Debt/Equity of 0.5 (per the Roarable RQD rating). A Piotroski score of 2 out of 9 signals weak financial-health signals, and this is the pillar with the most moderate reading.

The overall implication: the rating frames EXOZ as a high-risk name where weak cash generation, weak insider and institutional signals, and a weak forensic profile all point the same direction. A prospective investor should treat the 52-week range ($3.24 to $18.4) and the current price of 4.11 as evidence of severe price volatility, and recognize that the valuation case depends on a turnaround the source data does not yet confirm.

Business

eXoZymes Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry (per the company profile). The profile reports a market capitalization of $0.0B, which conflicts with the $38.2M market capitalization in market data. Customers, products, and revenue model details are not available in source data. The FY 2025 and FY 2024 filings report revenue of $0.0M, indicating no meaningful reported revenue in those periods (per the SEC financials).

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-9.7M	$-9.2M	N/A	$-6.7M	$3.0M	N/A
FY 2024	$0.0M	$-5.9M	$-5.9M	N/A	$-8.9M	$9.7M	N/A
FY 2023	$0.1M	$-1.8M	$-2.0M	N/A	$-1.2M	N/A	N/A

Per the SEC financials, the company reported losses at the operating and net levels in every listed period, with gross, operating, and net margins all shown as 0% in market data. Cash declined from $9.7M in FY 2024 to $3.0M in FY 2025, while FCF remained negative in each period. ROIC is -35% (per market data). The Altman Z-Score of 2.5 and Piotroski F-Score of 2/9 are cited in the Roarable RQD rating, and Debt/Equity is 0.5 (per the Roarable RQD rating); the balance sheet debt figures themselves are not available in source data.

Recent Catalysts & News Wire Analysis

Recent news items are all flagged with a YELLOW light and MARKET WIRE impact label (per recent news and catalysts). Key items:

A news item referencing a rare natural molecule central to the company's supplement plans (per recent news and catalysts). Detail on the program's stage or timing is not available in source data.
A report that the CCO sold $19,426 in stock (per recent news and catalysts), an insider sale a careful investor should note.
Reports of a 10,000-share stock option grant to a director at a $6.28 strike (per recent news and catalysts), and a separate report of a 10,000-stock-option grant to director James Joseph Lalonde (per recent news and catalysts).
A report that shares slipped 1.50% to $5.25 while holding above a $5.00 support level (per recent news and catalysts). This is not consistent with the current price of 4.11 in market data, so the timing and reliability of this figure should be verified.

Proprietary signals: none are reported in the Butterfly Supply-Chain Graph. Risk watch items are the insider sale, the price-level discrepancy above, and the absence of reported revenue.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlations are therefore not available in source data. Second-order bottlenecks cannot be identified from the provided sources. A prospective investor should note that the absence of mapped dependencies is itself a gap in the research, not evidence of independence.

Open Questions

What is the company's revenue model, and when, if ever, is revenue expected to begin, given reported revenue of $0.0M in FY 2024 and FY 2025?
What are the debt balances behind the reported Debt/Equity of 0.5, and how much runway does the $3.0M cash balance provide at the FY 2025 burn rate?
What is the status and timeline of the rare natural molecule supplement program referenced in recent news?
Why do the market capitalization figures conflict ($0.0B in the profile versus $38.2M in market data), and which figure is correct?
What drove the reported price of $5.25 in the news wire versus the current price of 4.11, and is there any institutional or analyst coverage to confirm either level?

EXOZ Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for eXoZymes Inc. (EXOZ) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EXOZ Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 12h ago

eXoZymes Inc. Estimates – NASDAQ:EXOZ

TradingView report covering eXoZymes Inc. (EXOZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 15h ago

A rare natural molecule is central to eXoZymes' plans for supplements

Stock Titan report covering eXoZymes Inc. (EXOZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com Nigeria • 18h ago

Exozymes CCO Damien Perriman sells $19,426 in stock By Investing.com

Investing.com Nigeria report covering eXoZymes Inc. (EXOZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 21h ago

eXoZymes (EXOZ) Slips 1.50% to $5.25 as Shares Hold Above $5.00 Support - Butterfly Setup

https://www.siam.in/ report covering eXoZymes Inc. (EXOZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Options for 10,000 shares at $6.28 go to Exozymes (EXOZ) director Marlett.

Stock Titan report covering eXoZymes Inc. (EXOZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Kalkine Media • 1d ago

Exozymes Inc. Director James Joseph Lalonde Granted 10,000 Stock Options

Kalkine Media report covering eXoZymes Inc. (EXOZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A director receives a 10,000-share option from ExoZymes (EXOZ), with a $6.28 exercise price.

Stock Titan report covering eXoZymes Inc. (EXOZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Kalkine Media • 1d ago

Exozymes' CCO Damien Perriman Sells 3,729 Shares Following RSU Vesting

Kalkine Media report covering eXoZymes Inc. (EXOZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EXOZ Bull vs. Bear Conversation Board — What's Your Call at $4.13?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EXOZ 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $3.62 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is EXOZ (E • RQD 32/100) a Buy at $4.11?

Welcome to the EXOZ (eXoZymes Inc.) Roar Pit. Current RQD Composite is 32/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $3.29 (-20.0%)

Spot @ $4.11

Pump the brakes on EXOZ — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on EXOZ, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless eXoZymes Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $5.06 (+23.1%)

Spot @ $4.11

EXOZ cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on EXOZ, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $4.11 (52-wk range $3.24 - $18.40), any beat on forward guidance forces shorts and underweight funds to chase.